Reclaiming Global Public Health
The promise of COVID vaccines has been unevenly realized: fault lines have emerged between those able to secure doses and those left behind.

The promise of COVID vaccines has been unevenly realized: fault lines have emerged between those able to secure doses and those left behind.

This post explains why Moderna’s cynical attempt to take back its COVID-19 vaccine patent pledge should fail.

For COVID treatments and diagnostics to be broadly available at affordable prices, their IP must be considered a global public good.

Putting vaccine equity at the center of a pandemic treaty will already be a huge step towards global health’s decolonization.

The pandemic has laid bare the lack of regulation for the sharing of intellectual property needed for an effective and equitable response.

The COVID-19 pandemic has brought into sharp relief longstanding equity problems surrounding the allocation of newly developed vaccines.

Activists in the access-to-medicines movement have mobilized to combat the threat of vaccine/therapeutic apartheid during the COVID-19 pandemic.

Going forward, practical solutions should focus on scaling up manufacturing and supply, and improving access and affordability.

An explanation of the WTO waiver of COVID-19 intellectual property, what the U.S. declaration of support means, and likely effects of the waiver.

Should a waiver be issued, there is no legal mechanism that can compel the transfer of certain types of know-how or trade secrets.
